How to Build a Pharma GTM Strategy That Actually Launches Well
Only 14.3% of compounds that enter Phase I ever reach FDA approval. Of those that do, just 1 in 10 launched during 2020-2024 exceeded $100M in first-year sales - down from 1 in 5 during 2015-2019. An analysis of 26,000+ oncology providers found that roughly 20% adopt a new therapy within two years of launch. That's it.
The traditional 6-12 month launch window is dead. It's now a 36-month success horizon, and if your pharma GTM strategy doesn't start years before approval, you're already behind.
The short version: Start 36-48 months before approval. Prioritize market access and medical affairs before commercial model design. Treat post-prescribing barriers - access, support, affordability - as seriously as clinical differentiation. Product attributes explain only 10-20% of prescribing behavior. The rest is people, services, and reputation.
What Pharma GTM Strategy Actually Covers
Pharma go-to-market planning isn't SaaS GTM with a compliance layer bolted on. You're navigating regulators, payers, providers, and patients simultaneously - each with different evidence thresholds, decision timelines, and incentive structures. A complete strategy spans five pillars, and every one of them has to work together or the launch stalls.
Let's break them down.
Five Pillars of a Pharma Launch
Market Access & Payer Strategy
This is where launches are won or lost. It has to start 36 months before approval for primary care, 48 months for specialty and rare disease. Payers demand strong health-economic evidence alongside clinical data, and trial design must satisfy both regulatory and HTA needs from the start. Durable payer rejections now affect 60%+ of new patients for some therapies, making early engagement existential rather than optional.
The cautionary tale: Sanofi's Zaltrap. Priced at a premium to Avastin without a compelling economic case, it faced immediate backlash and a 50% price cut within weeks of launch.
The regulatory environment keeps tightening. The EU's Joint Clinical Assessment process went live in January 2025 and initially applied to oncology and ATMPs, adding another evidence layer for European launches in 2026 and beyond. In the US, Medicare price negotiations under the Inflation Reduction Act are squeezing margins further. If your health economics team isn't embedded in trial design from the start, you're building a product the market won't pay for.
Medical Affairs Integration
Medical affairs isn't a support function. It's a go-to-market pillar.
62% of EU KOLs and 48% of US KOLs want MSL engagement before or during Phase 3 trials - not after approval, not at launch. High performers begin these engagements 18-24 months before launch. By the time reps hit the field, the scientific narrative should already be established in the minds of the physicians who matter most. Teams that treat medical affairs as an afterthought consistently underperform those that treat it as a lead function.
Segmentation & Targeting
Traditional decile-based segmentation - ranking HCPs by prescribing volume and calling the top ones - isn't enough anymore. BCG's Demand-Centric Growth methodology uses machine learning across thousands of prescribing decisions to build demand trees that reveal why physicians choose one therapy over another, not just how much they prescribe.
In one post-launch case, refocusing targeting based on ML-derived demand insights drove 50%+ quarterly growth for multiple consecutive quarters. In a late-lifecycle example, the same approach reduced 15+ messages down to 3 and condensed a 150-page visual aid to 15 pages in under six weeks.
Better targeting doesn't just improve efficiency. It changes trajectory.
Commercial Model Design
Your field team faces brutal math: oncologists receive 152 pharma display ads per month and nearly 9 rep visits per day. Physicians find only about one-third of sales calls valuable, and 90% of interactions last under two minutes. Over 20% of high-value physicians now restrict rep access entirely.
Most companies are moving to hybrid field-plus-digital models, but execution is harder than strategy decks suggest. In a 2023 survey of 100 senior commercial leaders, data availability and integrity ranked as the #1 barrier to hybrid GTM at 22%, followed by marketing ROI attribution at 19%. Orchestration beats volume - but orchestration requires clean data and cross-functional alignment that most organizations still lack. Typical sales force effectiveness spend runs $4-6M annually, which makes getting the model right a high-stakes bet.
Patient Journey & Support
Here's the thing: nearly 60% of pharma launches underperform in their first year. The recurring root cause? Teams don't understand the real patient journey until it's too late.
ZS research shows 70-80% of launch team effort targets "why to prescribe" while only 20-30% addresses "how to treat" - the post-prescribing barriers like prior authorization complexity, affordability, monitoring burden, and site-of-care constraints. A typical launch faces 25-65 discrete barriers between prescription and sustained therapy. Teams that map these barriers 18+ months before launch consistently outperform those that discover them reactively.
Pharma GTM starts 36 months before approval - and your MSL team needs verified contact data for every KOL on day one. Prospeo gives you 98% accurate emails and 125M+ verified mobile numbers with 30% pickup rates, so your medical affairs team reaches the right physicians before competitors do.
Stop losing launch momentum to bounced emails and bad phone numbers.
The Differentiation Paradox
Physicians say product attributes drive 42% of their prescribing loyalty. But when you decompose actual behavior, product explains only 10-20% of adoption. What actually drives it? People (29%), support services (29%), and reputation (18%).
Clinical differentiation alone barely moves the needle. ZS data shows that clinical differentiation lifts the probability of overperformance from 44% to just 49%. Combine clinical differentiation with strong manufacturer commitment - MSL relationships, hub services, payer access, peer-to-peer programs - and overperformance jumps to 67%. One-third of clinically differentiated launches still fail to meet expectations three years post-launch.
Clinical superiority gets you to the table. Everything else determines whether you stay. We've seen teams pour resources into messaging clinical differentiation while neglecting the infrastructure that actually converts prescribing intent into filled prescriptions. That's a recipe for a launch that looks great on paper and disappoints in the real world.
GTM Pitfalls That Kill Launches
Five patterns show up repeatedly in underperforming launches:
- Weak differentiation positioning - clinical data exists, but the value story doesn't resonate with payers or providers in their language.
- Insufficient market access preparation - payer evidence gaps discovered too late to address before launch.
- Ignoring competitive counter-moves - competitors adjust pricing, expand labels, or increase field presence, and you have no scenario plan.
- Misaligned internal teams - commercial, medical, and access functions operating from different timelines and different data.
- No post-launch feedback loop - in our experience, this is the most common failure. Teams treat launch day as the finish line instead of the starting gun for a 36-month optimization cycle.
Specialty products typically take 3-5 years to reach peak sales. If you aren't iterating through that entire window, you're leaving revenue on the table.
Building Your HCP Target List
Segmentation is only as good as the data underneath it. When your reps and MSLs get under two minutes with an oncologist - and over 20% of physicians restrict access entirely - every contact has to be verified, current, and reachable. Industry-average refresh cycles are around six weeks, which means a list can go stale fast and waste access windows you can't get back.
For teams building or refreshing HCP target lists, Prospeo covers 300M+ professional profiles with 98% email accuracy, 143M+ verified emails, 125M+ verified mobile numbers, and a 7-day data refresh cycle. Pair its 30+ search filters with your segmentation model, export verified contacts, and push them directly into your CRM or engagement platform. Skip this if you already have a reliable data vendor with weekly refresh - but if your bounce rates are creeping above 5%, it's worth testing.
If 20% of high-value physicians restrict rep access, your commercial team needs direct dials and verified emails - not gatekept switchboards. Prospeo's 30+ search filters let you segment HCPs by role, company size, and department, then deliver contact data refreshed every 7 days at $0.01 per email.
Reach restricted-access physicians directly with data that's never more than a week old.
FAQ
How far before launch should pharma GTM planning start?
Thirty-six months for primary care, 48 months for specialty and rare disease. Market access and medical affairs work must begin earliest - payer evidence gaps and KOL relationships can't be built in the final year before approval.
What's the biggest reason pharma launches underperform?
Over-investing in clinical messaging while under-investing in post-prescribing barriers. ZS data shows 70-80% of launch effort targets "why to prescribe" when adoption depends more on access, support services, and reputation than on clinical differentiation alone.
How is a pharma GTM strategy different from SaaS GTM?
Pharma go-to-market involves simultaneous stakeholder management across regulators, payers, providers, and patients - each with different evidence thresholds and decision timelines. Approval cycles run years instead of weeks, distribution requires specialty pharmacy networks and cold-chain logistics, and promotional activity is governed by FDA regulations that don't exist in software. The planning horizon alone, 36-48 months, dwarfs anything in SaaS.
How do commercial teams build accurate HCP target lists?
Start with your segmentation model, then validate contacts through a B2B data platform with verified emails and direct dials. A 7-day data refresh cycle and 98% email accuracy ensure your field team avoids wasting limited HCP access time on outdated contacts. The free tier at Prospeo includes 75 email credits per month - enough to test before committing.